Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 2/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.34 |
| ▸ | ERN1 | O75460 | 3/20 | 0.33 |
| ▸ | BACE1 | P56817 | 2/20 | 0.33 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.33 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.33 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.33 |
| ▸ | BTK | Q06187 | 1/20 | 0.33 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15363725 | 0.81 | CYP11B2 (0.31) | CYP11B2 | |
| SCHEMBL458891 | 0.78 | PIK3CD (0.37) | PIM2PIK3CD | |
| SCHEMBL15363590 | 0.76 | PIK3CD (0.39) | CYP11B2CYP11B1BACE1PIM1PIM3 | |
| SCHEMBL15363589 | 0.73 | — | — | |
| SCHEMBL458722 | 0.71 | ERN1 (0.45) | CYP11B2CYP11B1ERN1 | |
| SCHEMBL4182889 | 0.71 | ALDH1A1 (0.42) | ERN1PIK3CD | |
| SCHEMBL457871 | 0.71 | DHODH (0.44) | — | |
| SCHEMBL4185848 | 0.71 | ERN1 (0.46) | ERN1PIK3CD | |
| SCHEMBL29683769 | 0.70 | ALDH1A1 (0.46) | — | |
| SCHEMBL5116 | 0.70 | ALDH1A1 (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2614061-B1 | QUINOLINE AND QUINOXALINE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA SA (BE) | 2015-05-20 | — | — | EP | disclosed |
| US-9029392-B2 | Quinoline derivatives as kinase inhibitors | UCB PHARMA S.A. (BE) | 2015-05-12 | — | — | US | disclosed |
| US-20130296338-A1 | Quinoline and Quinoxaline Derivatives as Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2013-11-07 | — | — | US | disclosed |
| EP-2614061-A1 | QUINOLINE AND QUINOXALINE DERIVATIVES AS KINASE INHIBITORS | UCB Pharma, S.A. (BE) | 2013-07-17 | — | — | EP | disclosed |
| WO-2012032334-A1 | QUINOLINE AND QUINOXALINE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2012-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130296338-A1 | Quinoline and Quinoxaline Derivatives as Kinase Inhibitors | MAP3K13, MAP4K3, MAP3K3 | CYP11B2 3986/4885CYP11B1 3708/4885ERN1 713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.